Portal Venous Tumor Thrombosis and Visceral Organ Metastasis without Skeletal Involvement in mCRPC: Adverse Prognostic Indicators on Dual Tracer PET/CT and Clinical Outcome after <sup>177</sup> Lu-PSMA-617 PRLT and Cabazitaxel Therapy.

导出 OA

翻译打印收藏纠错

作者： Yeshwanth,Edamadaka ^[1] ; Rahul V,Parghane ^[1] ; Sandip,Basu ^[1]

作者单位： Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai, India.;Homi Bhabha National Institute, Mumbai, India. ^[1]

关键词 177 Lu-PSMA-617 radioligand therapy 18 F-FDG-PET/CT 68 Ga-PSMA-11 PET/CT liver metastasis metastatic castration-resistant prostate cancer portal venous tumor thrombosis prostate cancer

DOI 10.1055/s-0044-1788736

PMID 39677344

发布时间 2025-01-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

World journal of nuclear medicine

2024年23卷4期

302-306页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Portal Venous Tumor Thrombosis and Visceral Organ Metastasis without Skeletal Involvement in mCRPC: Adverse Prognostic Indicators on Dual Tracer PET/CT and Clinical Outcome after <sup>177</sup> Lu-PSMA-617 PRLT and Cabazitaxel Therapy.

World journal of nuclear medicine

相似文献

World journal of nuclear medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Portal Venous Tumor Thrombosis and Visceral Organ Metastasis without Skeletal Involvement in mCRPC: Adverse Prognostic Indicators on Dual Tracer PET/CT and Clinical Outcome after <sup>177</sup> Lu-PSMA-617 PRLT and Cabazitaxel Therapy.

World journal of nuclear medicine

相似文献

World journal of nuclear medicine

相关期刊

检索历史清除